Representatives from CAPS will be at booth #1101 at the 55th AmSECT conference, April 29-May 2, at the Hynes Convention Center in Boston.

“Tromethamine 0.3 molar solution is now available from CAPS, where improving patient care and outcomes have been a tradition for more than 25 years,” said Mike Koch, Senior Vice President, CAPS Professional Services. “In keeping with that commitment, we’re supplying this important medication to help clinicians.”

CAPS Tromethamine solution is now available and supplied as a single dose 0.3M 50mL solution in a 60 mL syringe with a tamper-evident syringe cap. The cap easily unlocks, just prior to syringe use, by pulling the clear protective barrier off and removing the red syringe cap.

Like all CAPS sterile compounded drugs, Tromethamine undergoes CAPS’ Test, Hold and Release (THRSM) program which is designed to ensure that every compounded drug batch from its 503B outsourcing facilities meets the new standards for cGMP release testing for sterility, potency, and endotoxin testing prior to release and shipment. CAPS also offers a Certificate of Release for each batch to give customers peace of mind.

CAPS, a B. Braun company, was among the first outsourcing admixture pharmacies in the nation to adopt release testing.